Literature DB >> 7812791

Investigations of neurotoxicity and neuroprotection within the nucleus basalis of the rat.

G L Wenk1, W Danysz, S L Mobley.   

Abstract

The present study investigated the specific ways by which cytotoxicity due to glutamate receptor stimulation could be attenuated by the administration of agonists and antagonists of the ionotropic and metabotropic glutamate receptors within the nucleus basalis magnocellularis (NBM) of rats as measured by cortical choline acetyltransferase activity. The results of these studies suggest that (1) the cytotoxicity of ibotenate to NBM cholinergic cells is not dependent upon stimulation of metabotropic glutamate receptors, but results from activation of N-methyl-D-aspartate (NMDA) receptors, (2) the cytotoxicity of quisqualate to cholinergic cells within the NBM is not dependent upon stimulation of NMDA or metabotropic receptors, and (3) the cytotoxicity of NMDA was prevented by administration (i.p.) of the un-competitive NMDA antagonist memantine (30 mg/kg), resulting in plasma levels of 2.5 micrograms/ml, a concentration known to block efficiently NMDA receptors in vitro. Finally, performance of a food-motivated, delayed-alternation task on a T-maze was impaired by injections of NMDA into the NBM, but was prevented by co-administration of NMDA with memantine.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7812791     DOI: 10.1016/0006-8993(94)91590-3

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  11 in total

1.  Neuroprotective potential of ionotropic glutamate receptor antagonists.

Authors:  Wojciech Danysz; Chris G Parsons
Journal:  Neurotox Res       Date:  2002-03       Impact factor: 3.911

Review 2.  Multi-target design strategies in the context of Alzheimer's disease: acetylcholinesterase inhibition and NMDA receptor antagonism as the driving forces.

Authors:  Michela Rosini; Elena Simoni; Anna Minarini; Carlo Melchiorre
Journal:  Neurochem Res       Date:  2014-02-04       Impact factor: 3.996

3.  Neuroprotective and symptomatological action of memantine relevant for Alzheimer's disease--a unified glutamatergic hypothesis on the mechanism of action.

Authors:  W Danysz; C G Parsons; H J Mobius; A Stoffler; G Quack
Journal:  Neurotox Res       Date:  2000       Impact factor: 3.911

4.  Efficacy of local polymer-based and systemic delivery of the anti-glutamatergic agents riluzole and memantine in rat glioma models.

Authors:  Kaleb Yohay; Betty Tyler; Kyle D Weaver; Andrea C Pardo; Dan Gincel; Jaishri Blakeley; Henry Brem; Jeffrey D Rothstein
Journal:  J Neurosurg       Date:  2014-01-31       Impact factor: 5.115

Review 5.  Non-cholinergic strategies for treating and preventing Alzheimer's disease.

Authors:  P Murali Doraiswamy
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

Review 6.  Anti-dementia drugs and hippocampal-dependent memory in rodents.

Authors:  Carla M Yuede; Hongxin Dong; John G Csernansky
Journal:  Behav Pharmacol       Date:  2007-09       Impact factor: 2.293

Review 7.  Multi-Target Drug Candidates for Multifactorial Alzheimer's Disease: AChE and NMDAR as Molecular Targets.

Authors:  Md Sahab Uddin; Abdullah Al Mamun; Md Tanvir Kabir; Ghulam Md Ashraf; May N Bin-Jumah; Mohamed M Abdel-Daim
Journal:  Mol Neurobiol       Date:  2020-09-15       Impact factor: 5.590

8.  Effects of memantine and MK-801 on NMDA-induced currents in cultured neurones and on synaptic transmission and LTP in area CA1 of rat hippocampal slices.

Authors:  T Frankiewicz; B Potier; Z I Bashir; G L Collingridge; C G Parsons
Journal:  Br J Pharmacol       Date:  1996-02       Impact factor: 8.739

Review 9.  The role of the N-methyl-D-aspartate receptor in Alzheimer's disease: therapeutic potential.

Authors:  P Murali Doraiswamy
Journal:  Curr Neurol Neurosci Rep       Date:  2003-09       Impact factor: 5.081

10.  Cholinergic modulation of event-related oscillations (ERO).

Authors:  Manuel Sanchez-Alavez; Patricia Robledo; Derek N Wills; James Havstad; Cindy L Ehlers
Journal:  Brain Res       Date:  2014-03-02       Impact factor: 3.252

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.